Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients
-
Published:2023-12
Issue:6
Volume:8
Page:102030
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Araki T.ORCID,
Kanda S.ORCID,
Ide T.,
Sonehara K.,
Komatsu M.,
Tateishi K.ORCID,
Minagawa T.,
Kiniwa Y.ORCID,
Kawakami S.,
Nomura S.,
Okuyama R.,
Hanaoka M.,
Koizumi T.
Subject
Cancer Research,Oncology
Reference43 articles.
1. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics;Twomey;AAPS J,2021
2. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade;Morad;Cell,2021
3. Checkpoint inhibitor pneumonitis: Mechanisms, characteristics, management strategies, and beyond;Reuss;Curr Oncol Rep,2020
4. Safety and efficacy of PD-1/PD-L1 inhibitors in treatment-naive and chemotherapy-refractory patients with non-small-cell lung cancer: a systematic review and meta-analysis;Khunger;Clin Lung Cancer,2018
5. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis;Nishino;JAMA Oncol,2016